These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 22368270)

  • 61. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
    Ravandi F; Alattar ML; Grunwald MR; Rudek MA; Rajkhowa T; Richie MA; Pierce S; Daver N; Garcia-Manero G; Faderl S; Nazha A; Konopleva M; Borthakur G; Burger J; Kadia T; Dellasala S; Andreeff M; Cortes J; Kantarjian H; Levis M
    Blood; 2013 Jun; 121(23):4655-62. PubMed ID: 23613521
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.
    Chen F; Ishikawa Y; Akashi A; Naoe T; Kiyoi H
    Oncotarget; 2016 Jul; 7(30):47018-47032. PubMed ID: 27331411
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
    Inaba H; van Oosterwijk JG; Panetta JC; Li L; Buelow DR; Blachly JS; Shurtleff S; Pui CH; Ribeiro RC; Rubnitz JE; Pounds S; Baker SD
    Clin Cancer Res; 2022 Jun; 28(12):2536-2546. PubMed ID: 35344039
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
    Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
    J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
    [TBL] [Abstract][Full Text] [Related]  

  • 68. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
    Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
    Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 71. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
    Metzelder SK; Schroeder T; Finck A; Scholl S; Fey M; Götze K; Linn YC; Kröger M; Reiter A; Salih HR; Heinicke T; Stuhlmann R; Müller L; Giagounidis A; Meyer RG; Brugger W; Vöhringer M; Dreger P; Mori M; Basara N; Schäfer-Eckart K; Schultheis B; Baldus C; Neubauer A; Burchert A
    Leukemia; 2012 Nov; 26(11):2353-9. PubMed ID: 22504140
    [TBL] [Abstract][Full Text] [Related]  

  • 72. FLT3/internal tandem duplication subclones in acute myeloid leukemia differ in their engraftment potential in NOD/SCID mice.
    Cheung AM; Chow HC; Kwong YL; Liang R; Leung AY
    Leuk Res; 2010 Jan; 34(1):119-22. PubMed ID: 19683812
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
    Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
    Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
    Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
    Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 77. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD
    Jiang L; Zhao Y; Liu F; Huang Y; Zhang Y; Yuan B; Cheng J; Yan P; Ni J; Jiang Y; Wu Q; Jiang X
    Cell Commun Signal; 2024 Aug; 22(1):391. PubMed ID: 39113090
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
    Guenounou S; Delabesse E; Récher C
    Eur J Haematol; 2014 Dec; 93(6):533-6. PubMed ID: 24689895
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review].
    Wei SN; Wei H; Mi YC; Liu BC; Liu KQ; Zhou CL; Li QH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):8-11. PubMed ID: 21429393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.